Please use this identifier to cite or link to this item: https://observatorio.fm.usp.br/handle/OPI/36382
Title: Brentuximab vedotin (BV) versus physician's choice (PC) of methotrexate or bexarotene in adult patients with previously treated CD30-positive cutaneous T-cell lymphoma (CTCL; mycosis fungoides [MF] or primary cutaneous anaplastic large cell lymphoma [pcALCL]): final time to next therapy (TTNT) results from the phase 3 ALCANZA study
Authors: SCARISBRICK, JuliaHORWITZ, Steven M.PRINCE, H. MilesWHITTAKER, SeanDUVIC, MadeleineKIM, Youn H.QUAGLINO, PietroZINZANI, Pier LuigiBECHTER, OliverERADAT, HerbertPINTER-BROWN, LaurenAKILOV, OlegGESKIN, LarisaSANCHES, JoseORTIZ-ROMERO, PabloLISANO, JulieBROWN, LisaBUNN, VeronicaLITTLE, MeredithDUMMER, Reinhard
Citation: EUROPEAN JOURNAL OF CANCER, v.119, suppl.1, p.S31-S31, 2019
Appears in Collections:

Comunicações em Eventos - FM/MDT
Departamento de Dermatologia - FM/MDT

Comunicações em Eventos - HC/ICHC
Instituto Central - HC/ICHC

Comunicações em Eventos - LIM/53
LIM/53 - Laboratório de Micologia


Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.